The Mount Sinai Health System and the Icahn School of Medicine at Mount Sinai are leaders in the fields of immunology, allergies, and vaccinology. The Allergy and Immunology division at the Mount Sinai Health System, and the Division of Clinical Immunology at Icahn Mount Sinai, are both under the direction of Rachel Miller, MD. These departments lead the nation in researching immune deficiency diseases and allergy disorders and translating these findings to the design of pioneering treatments.
The Mount Sinai Health System and the Icahn School of Medicine at Mount Sinai are leaders in the fields of immunology, allergies, and vaccinology. The Allergy and Immunology division at the Mount Sinai Health System, and the Division of Clinical Immunology at Icahn Mount Sinai, are both under the direction of Rachel Miller, MD. These departments lead the nation in researching immune deficiency diseases and allergy disorders and translating these findings to the design of pioneering treatments.
A new study led by researchers at the Icahn School of Medicine at Mount Sinai has revealed key differences in gut bacteria and their metabolic byproducts in infants that may predict the development of peanut allergies by mid-childhood. ...
Miriam Merad, MD, PhD, an esteemed immunologist at the Icahn School of Medicine at Mount Sinai, has been elected to the National Academy of Medicine (NAM) in recognition of her pioneering contributions to the fields of immunology and cell biology.
How are advances in immunology transforming medical research and medical care? And how will these advances help to improve and prolong the lives of patients?
The Marc and Jennifer Lipschultz Precision Immunology Institute (PrIISM) is a scientific hub for all immunological research and cutting-edge immunotechnology centers at the Icahn School of Medicine at Mount Sinai.
A recent study in pancreatic cancer provided evidence for immunoediting in human cancers, opening up the potential for cancer vaccines that could improve survival and outcomes.
Nina Bhardwaj, MD, PhD, was honored with the 2022 ESMO Award for Immuno-Oncology from the European Society for Medical Oncology in recognition of her outstanding contributions to cancer immunology research.
Researchers at the Icahn School of Medicine at Mount Sinai have developed an innovative approach—demonstrated in mouse models and isolated human brain tissue—to safely and effectively deliver therapeutics into the brain, providing new ...
The therapy, known as a bispecific antibody, binds to both T cells and multiple myeloma cells and directs the T cells—white blood cells that can be enlisted to fight off diseases—to kill multiple myeloma cells.
Mount Sinai researchers have validated for the first time that a simple blood test called a liquid biopsy could be a better predictor of whether cancer immunotherapy will be successful for a patient with lung cancer than an invasive tumor biopsy procedure.
Scientists led by Miriam Merad, MD, PhD, have shown for the first time that specific populations of macrophages promote tumor growth and contribute to immune evasion in early lung cancer lesions.
One major limitation of T-cell-based immunotherapies is a phenomenon known as “antigen escape,” which occurs when a subset of cancer cells lose the targeted antigen.
Investigators at The Tisch Cancer Institute are developing different types of personalized vaccines, including those that treat cancers with common cell mutations and those combined with checkpoint inhibitors.
The U.S. Food and Drug Administration's recent approval of the adjuvant use of nivolumab for muscle-invasive urothelial carcinoma may set a new standard of care.
Filip Swirski, PhD, an internationally recognized leader in cardiovascular immunology research, is the inaugural Director of the new Cardiovascular Research Institute.
A long-term analysis conducted by leading microbiologists at the Icahn School of Medicine at Mount Sinai reveals that antibody responses induced by COVId-19 vaccines are long-lasting.
Mount Sinai Health System is leading the fight against hepatitis B, having launched a universal screening and vaccination campaign across New York City in the fall of 2022, while heading up the development of a bold new set of guidelines ...
Mount Sinai scientists, in collaboration with researchers from the Carlos III Health Institute (ISCIII) in Madrid, Spain, have located and identified alterations in the monkeypox virus genome that potentially correlate with changes in ...
The study is the first to look at COVID-19 vaccination status and outcomes in patients with heart failure and has indicated significant protective effects in this high-risk patient population.
Mount Sinai has launched a system of digital alerts that appear on the screens of primary care physicians when a patient in their offices is a candidate for testing, vaccination, or treatment for hepatitis B.
The New York State Department of Health has reported a case of paralytic polio in a young adult and the poliovirus has been found in the New York City sewer system.
The mpox virus is rare. Over the last few months there has been an increase in cases among people who have not traveled to areas where mpox was considered more common.
Investigators at The Tisch Cancer Institute are developing different types of personalized vaccines, including those that treat cancers with common cell mutations and those combined with checkpoint inhibitors.
A large study conducted by investigators at Mount Sinai and Reproductive Medicine Associates of New York found that vaccination against COVID-19 did not affect fertility outcomes in patients undergoing in-vitro fertilization.
